From tissue or stem-cell input to fully validated, banked, and assay-ready 3D organoid models - we provide a seamless, end-to-end workflow designed for translational research, drug discovery, and personalized medicine.
- Background
- Service Details
- Capabilities
- Deliverables
- Features
- FAQs
Why Organoids?
Unlike 2D monolayers, organoids better retain tissue architecture, multi-lineage composition, and functional phenotypes - resulting in significantly higher predictive power for drug screening and disease modeling.
- Lacks the native microenvironment and cell-cell/cell-matrix interactions.
- Simple cellular monolayer; fails to self-organize.
- Genomic drift and functional instability over passages.
- Poor predictability and translational value.
- Inadequate for Patient-Derived Models (PDOs).
2D Model
Limitations
Advantages of
Organoid
Technology
- Possesses complex 3D structure that closely resembles the native tissue architecture.
- Exhibits self-organization and contains multiple tissue-specific cell types.
- Maintains stable gene expression and tissue-specific functions for long-term culture.
- Offers high predictive and translational value for drug efficacy and toxicity screening.
- Enables the generation of Patient-Derived Organoids (PDOs), capturing individual patient heterogeneity.
Our Organoid Culture & Development Service
Organoid Model Establishment
We transform your inputs into viable 3D organoid models that retain the tissue- and patient-specific architecture and function.
PDO Establishment
Generation of Patient-Derived Organoids (PDOs) from primary tumor or healthy tissue biopsies (fresh or frozen) for personalized medicine and patient-specific drug screening.
iPSC/ESC Differentiation
Derivation of complex organoids (e.g., Brain, Kidney, Liver) from induced Pluripotent Stem Cells (iPSCs) or Embryonic Stem Cells (ESCs).
Custom Model Development
Optimization of culture conditions, matrix composition, and growth factor cocktails for novel or difficult-to-establish tissue types.
Organoid Culture & Expansion
Scalable Expansion & Standardization
High-volume, controlled propagation of organoids using automated liquid handling and proprietary defined, serum-free media systems. Delivers the batch-to-batch consistency and scale necessary for robust High-Throughput Screening (HTS) in 96- and 384-well formats.
Cryopreservation & Biobanking
Implementation of validated cryopreservation protocols to ensure high post-thaw viability and functional recovery. Guarantees the stability of your model, minimizes the risk of genetic drift, and provides a sustainable, readily accessible resource for future research.
Organoid Characterization
- Structural and Morphological Characterization
| Method | Result |
| Bright-field Imaging | Qualitative and quantitative assessment of morphology, size, and viability (e.g., confirming crypt-like or branching structures). |
| Immunofluorescent Staining (IF)/IHC | Qualitative and quantitative assessment of morphology, size, and viability (e.g., confirming crypt-like or branching structures). |
| Electron Microscopy (TEM/SEM) | Characterize cellular ultrastructure, polarity, and organelle morphology (e.g., mitochondria, bile canaliculi presence). |
- Functional Characterization
| Method | Purpose |
| Functional Fluorescent Imaging | Use dyes/substrates to verify specific tissue functions, such as ion transporter activity (e.g., CFTR swelling assays) or bile transporter functionality. |
| ELISA and Colorimetric Assays | Quantify secretome output (e.g., C-peptide secretion) in response to stimuli, assessing maturity and function. |
| Luciferase Assays | Measure enzyme activity, such as Cytochrome P450 (CYP) activity for drug metabolism in liver models. |
| Histochemical Staining | Detect and quantify specific secreted components (e.g., Alcian blue/PAS for mucus secretion). |
| Electrophysiology | Characterize electrophysiological properties, vital for excitable tissues (e.g., cardiac, neural, islet organoids). |
- Molecular Characterization
| Method | Purpose |
| RNA Sequencing (qPCR, bulk, scRNA-seq) | Quantify gene expression of marker genes, transcription factors, and differentiation markers to confirm cell identity and purity. |
| Genetic QC (STR, Mycoplasma, Sequencing) | Ensure model authenticity (STR), sterility (Mycoplasma), and genetic stability over passages. |
Our Capabilities
Our platform supports a broad range of tissue types and sample origins, leveraging advanced matrix systems and high-throughput culture technologies:
Multi-Tissue Expertise
- Gastrointestinal (intestine, stomach, colon)
- Liver & Pancreatic
- Lung / Airway
- Neural / Brain
- Kidney
- Tumor
Diverse Sample Sources
- Fresh tissue biopsies or surgical specimens
- Induced pluripotent stem cells (iPSCs)
- Embryonic stem cells (ESCs)
Advanced Culture Technologies
- Defined Matrices: Matrigel, synthetic hydrogels, and tissue-specific matrices
- Serum-free Media: Chemically defined media optimized for each tissue type
- 3D Bioprinting: Spatially organized organoid construction
Deliverables
Upon completion of a project, the following deliverable package is provided, depending on specific project needs:
- Assay-ready plates compatible with HTS
- Cryopreserved vials / organoid bank for long-term storage and resuscitation
- Comprehensive QC certification package
- High-resolution imaging data (e.g., micrographs, immunostaining)
- Annotated sequencing datasets (optional)
Why Choose Us? Your Partner in 3D Biology
- Broad tissue coverage & flexible sample input
From GI, liver, lung, kidney, brain to tumor/PDO models; using biopsy tissue, tumor specimens, or iPSC/ESC. - Full-service, end-to-end solutions
We cover the entire workflow from sample to banked organoids or ready-to-use plates. - Scalable & high-throughput
Well-equipped to support 96-/384-well formats, ideal for drug screening, toxicity testing, or larger projects. - Rigorous quality assurance & reproducibility
Full QC, authentication, sterility, and batch consistency testing protocols in place.
FAQs
Q: What sample types can you accept to generate organoids?
A: We accept a variety of inputs, including primary tissue biopsies, tumor resections, patient-derived samples, iPSC/ESC lines, or other validated stem-cell sources. Our team can consult on optimal sample collection and shipping.
Q: Do you offer functional assays on the organoids?
A: Yes. In addition to basic QC, we offer a range of functional assays, including barrier integrity (TEER), cell viability, drug dose-response, and co-culture assays (e.g. with immune cells).
Q: Can organoids be genetically modified?
A: Yes, we offer gene editing services for organoids, including knock-out, knock-in, and base editing applications. Modified organoids undergo full characterization to confirm genetic alterations.
Q: How do you ensure reproducibility between batches?
A: We have strict SOPs and comprehensive QC testing in place. In addition, we use statistical process control to ensure batch-to-batch consistency. Each batch goes through morphology assessment, viability testing, and functional characterization.
Q: Do you offer custom protocol development?
A: Yes, our scientific team can develop customized protocols for specific research needs, novel tissue types, or unique applications not covered by our standard protocols.
Online Inquiry